Target intelligence / Profile preview

Actin alpha skeletal muscle (ACTA1) and Actin alpha smooth muscle (ACTA2) (ACTA1/ACTA2)

Target
ACTA1/ACTA2
Molecular classification
Actin family, Cytoskeletal protein, ATPase, Structural protein
01

Overview

Actin alpha isoforms ACTA1 and ACTA2 are highly conserved proteins that serve as essential components of the contractile apparatus in skeletal and smooth muscle, respectively (UniProt P68133, P62736). ACTA1 (alpha-skeletal muscle actin) is the predominant actin in adult skeletal muscle thin filaments, where it interacts with myosin to drive muscle contraction (MedlinePlus, 2016). Mutations in ACTA1 are a leading cause of congenital myopathies, such as nemaline myopathy, characterized by severe muscle weakness and the presence of protein aggregates called nemaline bodies (Nowak et al., 2012). ACTA2 (alpha-smooth muscle actin) is primarily expressed in vascular smooth muscle cells and is critical for maintaining vascular tone and blood pressure (Guo et al., 2007). Mutations in ACTA2 are associated with a spectrum of vascular diseases, including familial thoracic aortic aneurysms and dissections (TAAD) and multisystemic smooth muscle dysfunction syndrome (MSMDS) (Milewicz et al., 2010). Beyond its role in contraction, ACTA2 is a hallmark marker of activated myofibroblasts in fibrosis and the tumor microenvironment, making it a target of interest for anti-fibrotic and oncology therapies (Wikipedia, 2024). While direct targeting of actin is challenging due to its ubiquity and structural conservation, therapeutic strategies include small-molecule modulators of the contractile complex like Tirasemtiv, which sensitizes the thin filament to calcium, and novel approaches such as base editing to correct pathogenic mutations (Squire et al., 2011; Kleinstiver et al., 2025). Additionally, research compounds like Cytochalasins and Latrunculins are widely used to study actin dynamics, though their clinical utility is limited by systemic toxicity (SCBT, 2024).

Other names
Alpha-skeletal actinAlpha-smooth muscle actinalpha-SMAASMAAAT6ACTSAMYMY5NEM3CFTDActin alpha 1Actin alpha 2
02

Mechanism of action

Troponin activation to sensitize the actin-containing thin filament to calcium, thereby increasing contractile force; stabilization of mutant actin filaments to restore structural integrity; sequestration of actin monomers or capping of filament ends to disrupt polymerization dynamics; modulation of gene expression through nuclear translocation and SRF/MRTF-A signaling.

03

Biological functions

Muscle contractionCell motilityCytoskeleton organizationVascular contractilityMyofibroblast differentiationBlood pressure homeostasisVesicle trafficking
04

Disease associations

Nemaline myopathyThoracic aortic aneurysm and dissection (TAAD)Multisystemic smooth muscle dysfunction syndrome (MSMDS)Moyamoya diseaseCongenital fiber-type disproportionFibrosis (liver, lung, kidney)Cancer (stromal remodeling and chemoresistance)
05

Safety considerations

Potential for off-target effects on other highly conserved actin isoforms (e.g., cardiac or cytoplasmic actins)Systemic toxicity due to disruption of the essential cellular cytoskeletonSevere hypotension associated with smooth muscle actin modulationMuscle fatigue or hypertonia depending on the direction of modulation
06

Interacting drugs

Tirasemtiv (CK-2017357)

8 more in the full profile.

07

Biomarkers

Alpha-smooth muscle actin (alpha-SMA) protein expressionNemaline bodies (rods) in muscle biopsyACTA1/ACTA2 pathogenic genetic variantsG-actin to F-actin ratio

Beyond the preview

Go deeper on Actin alpha skeletal muscle (ACTA1) and Actin alpha smooth muscle (ACTA2) (ACTA1/ACTA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actin alpha skeletal muscle (ACTA1) and Actin alpha smooth muscle (ACTA2) (ACTA1/ACTA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call